Cargando…
High-content CRISPR screening in tumor immunology
CRISPR screening is a powerful tool that links specific genetic alterations to corresponding phenotypes, thus allowing for high-throughput identification of novel gene functions. Pooled CRISPR screens have enabled discovery of innate and adaptive immune response regulators in the setting of viral in...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721350/ https://www.ncbi.nlm.nih.gov/pubmed/36479127 http://dx.doi.org/10.3389/fimmu.2022.1041451 |
_version_ | 1784843754929127424 |
---|---|
author | Holcomb, Erin A. Pearson, Ashley N. Jungles, Kassidy M. Tate, Akshay James, Jadyn Jiang, Long Huber, Amanda K. Green, Michael D. |
author_facet | Holcomb, Erin A. Pearson, Ashley N. Jungles, Kassidy M. Tate, Akshay James, Jadyn Jiang, Long Huber, Amanda K. Green, Michael D. |
author_sort | Holcomb, Erin A. |
collection | PubMed |
description | CRISPR screening is a powerful tool that links specific genetic alterations to corresponding phenotypes, thus allowing for high-throughput identification of novel gene functions. Pooled CRISPR screens have enabled discovery of innate and adaptive immune response regulators in the setting of viral infection and cancer. Emerging methods couple pooled CRISPR screens with parallel high-content readouts at the transcriptomic, epigenetic, proteomic, and optical levels. These approaches are illuminating cancer immune evasion mechanisms as well as nominating novel targets that augment T cell activation, increase T cell infiltration into tumors, and promote enhanced T cell cytotoxicity. This review details recent methodological advances in high-content CRISPR screens and highlights the impact this technology is having on tumor immunology. |
format | Online Article Text |
id | pubmed-9721350 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97213502022-12-06 High-content CRISPR screening in tumor immunology Holcomb, Erin A. Pearson, Ashley N. Jungles, Kassidy M. Tate, Akshay James, Jadyn Jiang, Long Huber, Amanda K. Green, Michael D. Front Immunol Immunology CRISPR screening is a powerful tool that links specific genetic alterations to corresponding phenotypes, thus allowing for high-throughput identification of novel gene functions. Pooled CRISPR screens have enabled discovery of innate and adaptive immune response regulators in the setting of viral infection and cancer. Emerging methods couple pooled CRISPR screens with parallel high-content readouts at the transcriptomic, epigenetic, proteomic, and optical levels. These approaches are illuminating cancer immune evasion mechanisms as well as nominating novel targets that augment T cell activation, increase T cell infiltration into tumors, and promote enhanced T cell cytotoxicity. This review details recent methodological advances in high-content CRISPR screens and highlights the impact this technology is having on tumor immunology. Frontiers Media S.A. 2022-11-21 /pmc/articles/PMC9721350/ /pubmed/36479127 http://dx.doi.org/10.3389/fimmu.2022.1041451 Text en Copyright © 2022 Holcomb, Pearson, Jungles, Tate, James, Jiang, Huber and Green https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Holcomb, Erin A. Pearson, Ashley N. Jungles, Kassidy M. Tate, Akshay James, Jadyn Jiang, Long Huber, Amanda K. Green, Michael D. High-content CRISPR screening in tumor immunology |
title | High-content CRISPR screening in tumor immunology |
title_full | High-content CRISPR screening in tumor immunology |
title_fullStr | High-content CRISPR screening in tumor immunology |
title_full_unstemmed | High-content CRISPR screening in tumor immunology |
title_short | High-content CRISPR screening in tumor immunology |
title_sort | high-content crispr screening in tumor immunology |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721350/ https://www.ncbi.nlm.nih.gov/pubmed/36479127 http://dx.doi.org/10.3389/fimmu.2022.1041451 |
work_keys_str_mv | AT holcomberina highcontentcrisprscreeningintumorimmunology AT pearsonashleyn highcontentcrisprscreeningintumorimmunology AT jungleskassidym highcontentcrisprscreeningintumorimmunology AT tateakshay highcontentcrisprscreeningintumorimmunology AT jamesjadyn highcontentcrisprscreeningintumorimmunology AT jianglong highcontentcrisprscreeningintumorimmunology AT huberamandak highcontentcrisprscreeningintumorimmunology AT greenmichaeld highcontentcrisprscreeningintumorimmunology |